Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Oral Obesity Therapies Market Expansion Outlook: What Revenue Opportunities Lie Ahead?
The oral obesity therapies market size has witnessed strong expansion in recent years. It is forecast to rise from $3.94 billion in 2025 to $4.32 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.7%. This historical growth can be attributed to several factors, including the increasing global prevalence of obesity, a heightened awareness of metabolic health risks, the expansion of prescription-based weight management drugs, increased clinical research on appetite regulation mechanisms, and a growing healthcare focus on non-invasive obesity treatments.
The oral obesity therapies market size is anticipated to experience significant expansion in the upcoming years. It is forecast to grow to $6. 32 billion by 2030, achieving a compound annual growth rate (CAGR) of 9. 9%. This growth throughout the forecast period can be attributed to factors such as the increasing adoption of oral GLP-1 therapies, a rising demand for personalized metabolic treatments, the expansion of telemedicine-based obesity care, the development of next-generation oral incretin drugs, and increased investment by pharmaceutical companies in obesity drug pipelines. Major trends anticipated in this period include the rising adoption of oral GLP-1 based therapies for appetite regulation and weight management, an increasing use of combination oral obesity drugs targeting multiple metabolic pathways, a growing demand for personalized obesity treatment based on genetic and metabolic profiling, an expansion of telehealth-enabled prescription access for oral weight loss therapies, and the rising development of gut hormone modulating oral drugs for improved metabolic control.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample_request?id=21792040&type=smp
Oral Obesity Therapies Market Industry Drivers: What Is Driving Revenue Growth?
The increasing incidence of obesity is anticipated to boost the expansion of the oral obesity therapies market in the future. Obesity is defined as a medical state marked by an excessive buildup of body fat, elevating the likelihood of health issues like heart disease, diabetes, and hypertension. The primary reasons for the rise in obesity include greater intake of calorie-dense processed foods, resulting in surplus energy consumption and progressive weight gain if not offset by physical activity. Oral obesity therapies aid in managing obesity through the modulation of hunger-related hormones and the reduction of calorie absorption, thereby promoting long-term weight control and better health results. For example, data from May 2025, provided by the Office for Health Improvement and Disparities, a UK-based government body, indicated that in 2023–2024, the occurrence of overweight (inclusive of obesity) among adults was greater in men (69. 7%) than in women (59. 2%). Conversely, obesity by itself was marginally more common in women (26. 9%) compared to men (26. 2%). Consequently, the growing incidence of obesity is propelling the expansion of the oral obesity therapies market.
Oral Obesity Therapies Market Segmentation And Category Breakdown
The oral obesity therapies market covered in this report is segmented –
1) By Drug Class: Lipase Inhibitors, Sympathomimetic Appetite Suppressants, Combination Therapies, Oral GLP-1 Agonists, Other Oral Mechanisms
2) By Patient Indication: BMI ≥30 Primary Obesity, Overweight + Metabolic Comorbidities, Short-term Weight Reduction, Weight Maintenance, Adolescent Populations
3) By Sales Channel: Retail Pharmacies, Mail-order Pharmacies, Telehealth Platforms, Hospital Outpatient Pharmacies, Specialty Pharmacies
4) By Application: Obesity Management, Weight Loss Maintenance, Cardiometabolic Risk Reduction, Pre-Surgical Weight Control
5) By End User: Hospitals, Clinics, Homecare Settings
Subsegments:
1) By Lipase Inhibitors: Prescription Lipase Inhibitors, Over The Counter Lipase Inhibitors, High Dose Lipase Inhibitors, Low Dose Lipase Inhibitors, Generic Lipase Inhibitors, Branded Lipase Inhibitors
2) By Sympathomimetic Appetite Suppressants: Short Acting Appetite Suppressants, Long Acting Appetite Suppressants, Central Nervous System Stimulants, Adrenergic Appetite Suppressants, Prescription Appetite Suppressants, Extended Release Appetite Suppressants
3) By Combination Therapies: Appetite Suppressant And Antidepressant Combinations, Appetite Suppressant And Anticonvulsant Combinations, Multi Mechanism Combination Therapies, Fixed Dose Combination Therapies, Dual Mechanism Combination Therapies, Triple Mechanism Combination Therapies
4) By Oral Glucagon Like Peptide One Agonists: Daily Oral Glucagon Like Peptide One Agonists, Weekly Oral Glucagon Like Peptide One Agonists, High Potency Glucagon Like Peptide One Agonists, Sustained Release Glucagon Like Peptide One Agonists, Next Generation Incretin Agonists
5) By Other Oral Mechanisms: Serotonin Receptor Modulators, Metabolic Enhancers, Thermogenic Agents, Gut Hormone Modulators, Energy Expenditure Regulators, Dual Incretin Agonists
#Oral Obesity Therapies Market Growth Trends: What Is Influencing The Future Outlook?
Key companies operating in the oral obesity therapies market are focusing on developing innovative solutions, such as incretin-based therapy, to enhance weight loss efficacy, improve metabolic outcomes, and offer convenient non-injectable treatment options for patients. Incretin-based therapy refers to a class of treatments that mimic or enhance the action of incretin hormones (such as GLP-1) to regulate blood sugar levels, suppress appetite, and promote weight loss. For instance, in January 2026, Denmark A/S, a Denmark-based healthcare company, launched an LP-1 pill for obesity, called the Wegovy pill (oral semaglutide), for chronic weight management in adults with obesity or overweight plus related conditions, alongside diet and exercise. It’s also cleared to reduce cardiovascular risks such as heart attacks and strokes in those with established heart disease.
Oral Obesity Therapies Market Competitive Analysis Of Major Industry Participants
Major companies operating in the oral obesity therapies market are F. Hoffmann-La Roche AG, Merck & Co. Inc., Pfizer Inc., AstraZeneca PLC, Eli Lilly and Company, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, Sun Pharmaceutical Industries Ltd., Jiangsu Hengrui Medicine Co. Ltd., Celltrion Inc., Zydus Lifesciences Limited, Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Hanmi Pharmaceutical Co. Ltd., Innovent Biologics Inc., Viking Therapeutics Inc., Rhythm Pharmaceuticals Inc., Septerna Therapeutics, Eccogene Inc., Currax Pharmaceuticals LLC, Ascletis Pharma Inc., Structure Therapeutics
Access The Complete Oral Obesity Therapies Market Report:
https://www.thebusinessresearchcompany.com/report/oral-obesity-therapies-market-report
Oral Obesity Therapies Market Leading Geography: Which Region Generates The Most Revenue?
North America was the largest region in the oral obesity therapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral obesity therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.